HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - On March 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its audited annual results for the year ended 31 December 2025 (the "Reporting Period"). During the Reporting Period, the Company’s total revenue for the year was RMB 44,400.07 million, representing a year-on-year increase of 60%; profit for the year was RMB 2,095.22 million, a year-on-year surge of over 140%, demonstrating a leap in profitability and continued momentum for high-quality development.In core business sectors, the Company’s market share for both power batteries and energy storage cells climbed significantly. In October 2025, CALB’s power battery installations reached a historic milestone, ranking among the global top three for the first time on a monthly basis. In early 2026, the Company stood out in the battery industry again with a huge growth of 630% YoY in the commercial EV sector.Deepening Global Market Presence with Dual Breakthroughs in Premium Market Positioning and Large-Scale ProductionIn 2025, as the global new energy industry flourished, shipments of power batteries and energy storage cells soared, with overseas markets becoming the core growth engine. Backed by all-scenario product capabilities, CALB accelerated its strategic layout toward both premium positioning and large-scale development.The Company’s market share in the passenger vehicle sector reached a new high. Its 5C super-charged battery, which has reached a monthly delivery sale of 20,000+ sets, exclusively supports popular models such as XPeng’s new P7 long-range version, supporting Xpeng further enhance its market competitiveness with a record-breaking driving mileage of 3,961km within 24h. Furthermore, CALB successfully entered the supply chains of international OEMs such as Toyota, Volkswagen, and Hyundai. Simultaneously, the Company deepened strategic partnerships with HUAWEI and Xiaomi, laying the groundwork for mass-scale delivery in 2026.The commercial vehicle segment also saw explosive growth, with shipments achieving a multiple-fold increase in 2025. With over 468 new vehicle models announced, the Company achieved full-scenario coverage and showed strong momentum as commercial battery shipments surged 630% YoY in early 2026. Overseas, the Company secured major rail transit and bus projects in Europe and won multiple international client awards.In the energy storage market, CALB achieved dual breakthroughs. Internationally, the Company entered the top-tier supplier lists in South Africa, Latin America, the U.S., and Israel. The next-generation “ZHIJIU” 600Ah+ cell secured mass production nominations. Domestically, partnerships with giants like SPIC (State Power Investment Corporation Limited) and CTG (China Three Gorges Corporation) were strengthened, further advancing the all-category energy layout in energy storage.Furthermore, the Company has established a forward-looking presence in emerging new energy sectors such as ship, low-altitude economy, and robotics, which represents a core highlight for the capital markets. In the shipping sector, several benchmark projects have already been implemented with large-scale deliveries, providing solid support for stable earnings growth. In the low-altitude sector, powered by core solid-state battery technologies, the Company has successfully commenced mass production of batteries for flying cars and secured exclusive nominations for major eVTOL models, perfectly aligning with the development trend of a trillion-dollar market. In the robotics sector, the Company has completed its product layout based on breakthroughs in all-solid-state battery technology. With batch deliveries set to begin, the Company is preemptively securing its position in the core energy track for humanoid robots, opening up significant growth opportunities for its future performance.Continuous Technology Leadership and All-Scenario Product Matrix AdvancementIn 2025, CALB achieved key breakthroughs in high-performance batteries, solid-state batteries, and advanced manufacturing. Product series such as “UP,” “ZHIYUAN,” “ZHIJIU,” and “Boundless” continue to define industry trends.Specifically, CALB is leading the way in super-charged and high-power battery technologies. The Company’s 5C super-charged batteries have reached large-scale commercialization, while the 10C super-charged batteries completed design and development in 2025. The 20C high-power batteries developed for HEV/PHEV models have been delivered for mass production to Geely and Dongfeng. For the luxury supercar and racing segments, the Company has completed prototype testing of its 25C high-power batteries, which boast megawatt-level discharge capabilities. Additionally, the advanced R46 cells have reached mass production and are being supplied to top-tier eVTOL customers, securing the No.1 market share in the sector.Technological upgrades were also synchronized across energy storage and commercial battery sectors. The “ZHIYUAN” series achieved 2C super-charged for heavy-duty trucks and a long lifespan of 10 years or 2 million kilometers, while light commercial EV batteries can support an upgraded mileage of over 350 kilometers. The “ZHIJIU” 588Ah/684Ah cells achieve zero degradation for 3 years and 15,000+ cycles, with an energy density of 450Wh/L.Significant breakthroughs were made in next-generation battery technologies, specifically in hybrid solid-liquid and solid-state batteries. The 400Wh/kg hybrid solid-liquid battery took the lead in powering new energy commercial vehicles with batch installations. The 450Wh/kg “Boundless” solid-state battery completed its original system prototype verification with industry-leading performance. Meanwhile, the commercialization process in emerging sectors such as low-altitude economy and robotics is accelerating, which is expected to help the Company further expand its global market share. In addition, the Company will continue to be driven by the dual engines of “technological innovation and management innovation,” forging systematic competitiveness for the future by pursuing excellence in both performance and cost management.“AI + Energy” Strategy: Empowering Industrial UpgradingBuilding on technological breakthroughs and guided by the “AI + Energy” strategy, CALB is driven by technological innovation and guided by the “AI + Energy” strategy, adhering to the deep integration of technological innovation and industrial innovation. Propelled by a future-oriented R&D layout, the Company has established a positive feedback loop of “new technology and product development – multi-market application – scaled delivery – refined operations – technological iteration and upgrade”—fully aligning with the current industrial trend of convergence between AI and new energy.Currently, CALB has established global industrial clusters across China, Europe, and ASEAN, providing a solid foundation for its global business expansion and long-term high-quality development.As the global energy transition accelerates, global demands are poised for sustained and rapid growth, with emerging application scenarios continuously surfacing. It is anticipated that the Company’s market share and profitability will enter a phase of accelerated expansion, further bolstering its global competitiveness and industry influence.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - On 27 March, Ausnutria Dairy Corporation Ltd (Stock Code: 1717.HK, hereinafter referred to as "Ausnutria" or the "Company") officially released its 2025 annual results announcement. According to the announcement, Ausnutria achieved revenue of approximately RMB7.488 billion in 2025, representing a year-on-year increase of 1.2%. The Company recorded EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of approximately RMB518 million. Excluding the impact of one-off non-recurring items, core EBITDA reached approximately RMB616 million, demonstrating the Company's steady progress in navigating industry cycles. In 2025, driven by the dual engines of Family Nutrition and International Business, Ausnutria achieved resilient revenue growth while making significant breakthroughs in product category mix and regional market expansion. Notably, the international business of Kabrita has approached the RMB1 billion mark, with a compound annual growth rate exceeding 50% for three consecutive years, as its new global business ecosystem continues to take shape at an accelerated pace.Over the past year, the global economy has been marked by complexity and volatility, with heightened uncertainties arising from geopolitical tensions, inflation and exchange rate fluctuations. Compounded by intensifying competition amid a contracting domestic infant milk formula (IMF) market, the industry has faced multiple severe challenges. Against this backdrop, Ausnutria has maintained its strategic resolve, deepening its core strengths. The Company's international business has continued to unleash its growth momentum, while the Family Nutrition business has flourished across multiple fronts. Market share in core milk powder categories has steadily increased, and the level of refined management has improved significantly. Through these multi-dimensional efforts to enhance operational resilience, Ausnutria has laid a solid foundation for its long-term development.Kabrita International Business Approaches RMB1 Billion Mark with CAGR Exceeding 50% for Three Consecutive YearsIn 2025, Ausnutria further accelerated its internationalization efforts, continuously strengthening its comprehensive capabilities in global supply chain deployment, localised operations and digital collaboration, driving continued explosive growth in its overseas business. During the reporting period, revenue from the international business of Ausnutria's goat milk formula brand Kabrita recorded a year-on-year increase of 50.7% to approximately RMB974 million, making it the first infant goat milk formula brand from a Chinese dairy company to approach RMB1 billion in overseas sales. With a compound annual growth rate exceeding 50% for three consecutive years, the growing contribution of overseas markets has become increasingly prominent.Revenue from the Middle East market recorded a year-on-year increase of 65.5%, accounting for 45.7% of total overseas revenue and maintaining its position as Ausnutria's largest overseas sales market. Growth in this region was primarily driven by strong performance across established markets including Saudi Arabia, the UAE, Qatar and Kuwait, where the Company strengthened its promotion through medical and healthcare professional channels, continuously enhancing the medical endorsement of its goat milk formula products in these markets. Saudi Arabia delivered a particularly outstanding performance, leveraging deep collaborations with local maternity, infant care and medical institutions to effectively boost consumer acceptance and market penetration. Notably, Kabrita was awarded the "Fastest Growing Brand" accolade by Nahdi, the largest pharmacy retailer in the country. The newly entered Oman market in 2025 also exceeded expectations, injecting fresh momentum into the Company's growth.Revenue from the Commonwealth of Independent States (CIS) market recorded a year-on-year increase of 40.1%, accounting for 23.9% of total overseas revenue. As one of the Company's earliest overseas markets, the CIS market has achieved full product category coverage for Kabrita, encompassing infant formula, cereals, fruit purees, biscuits and more, comprehensively meeting the diverse consumer needs in the region. Through its "360° Omni-channel Marketing" strategy and "DTC Loyalty Program", the Company has engaged target consumers in a distinctive manner, building high value-added brand recognition and continuously consolidating and strengthening its core competitiveness in this market.Revenue from the North American market recorded a year-on-year increase of 39.5%, accounting for 22.2% of total overseas revenue. In 2025, Kabrita successfully entered Walmart, the largest retailer in the United States, and has now expanded into 780 stores, progressively developing both online and offline channels to reach a broader consumer base. In the newly entered Canadian market, the Company has been deepening its presence through the core Walmart channel while gradually building momentum on Amazon.In addition, the Company achieved 100% year-on-year growth in the Southeast Asian market by strengthening product differentiation through formula upgrades, with a particular focus on advancing digital community engagement and deepening collaboration with e-commerce channels and local platforms.Family Nutrition Achieves Steady Growth, Building Multi-dimensional Foundations for Future SuccessAs the Company's continuously nurtured "second growth curve" business, Ausnutria's nutrition products business achieved steady growth in 2025, with revenue recording a year-on-year increase of 5.2%. According to the announcement, this revenue growth was primarily attributable to continuous innovation in star probiotic strains and products, precise execution of channel strategies, and the sustained release of brand equity.Research-driven brand development. Ausnutria entered into a six-year strategic partnership with Jiangnan University, establishing the Joint Innovation Centre for Microecology and Functional Dairy as well as the Collaborative Innovation Centre for Probiotics, embarking on a new chapter of full-chain innovation collaboration. In the B2B segment, the Company achieved several key breakthroughs in probiotic strains: Bifidobacterium longum subsp. infantis YLGB-1496 was approved by the National Health Commission (NHC) for inclusion in the list of edible bacterial strains for infants and young children. With this approval, Ausnutria now possesses two nationally approved infant probiotic strains, earning its distinction as the "double champion" in China's infant probiotics field. Additionally, the independently developed Bifidobacterium animalis subsp. lactis CP-9 obtained the U.S. FDA GRAS (Generally Recognized as Safe) certification, marking Ausnutria's achievement of world-leading standards in research innovation and quality control. The continuous breakthroughs in strain technology provide strong and enduring core momentum for brand development. In the B2C segment in 2025, NC Stomach Care Powder and NC Nasal Comfort Probiotics maintained top rankings in category search popularity on Xiaohongshu. As certified by Euromonitor International, NC was awarded the title of "No.1 in National Sales of Australian Brand Nasal Sensitivity Probiotics".Innovation in response to emerging consumer demands. Bio(R) (Baoyichang(R)) Active Lactic Acid Bacteria Powder introduced a mini space capsule design, setting new aesthetic standards for probiotic products. Yili Changshi Probiotics, formulated with the patented BL-99 strain, achieved a top position on e-commerce bestseller lists. Diversified dosage form solutions, including instant-dissolve powder and micro-effervescent tablets, have effectively enhanced the product competitiveness of business partners. Throughout the year, NC launched 17 new products including G13 Growth Capsules and Sleep Well Probiotics, building a precision nutrition matrix covering gastrointestinal health, nasal sensitivity, sleep, growth, eye and brain health, liver and kidney health, and women's health.Channel upgrades fueling business development. The Company continued to deepen its presence in pharmaceutical channels, achieving simultaneous growth in both scale and pace of expansion. Collaboration with leading platforms was further strengthened, driving rapid growth in private domain e-commerce. The application of star probiotic strains was reinforced, enabling continued expansion of brand clientele. The Company also made breakthroughs in overseas market reach by expanding into European and North American markets. NC achieved steady growth on mainstream e-commerce platforms such as Tmall and JD.com, with the Stomach Care and Nasal Comfort product lines becoming leading brands in the cross-border health supplement category through channels such as Sam's Club and China Duty Free (CDF). The Company partnered with XKA and Fengxiangjia to develop its private domain presence, building an incremental online growth matrix. Offline, the Company consolidated its core client base, expanded into potential customer segments, and achieved initial results from pharmaceutical channel pilot programmes, laying a solid foundation for diversified business development.Domestic Milk Powder Business Steadily Increases Market Share, Solidifying Core FundamentalsChina's infant milk formula (IMF) industry is currently undergoing a period of deep structural adjustment, facing multiple pressures including overall market contraction, intensifying competition, and channel transformation, while birth rate fundamentals and channel structure remain under sustained pressure. During the reporting period, Ausnutria solidified its core fundamentals amid cyclical industry challenges, achieving steady growth in market share for its self-owned milk powder brands and recording overall revenue of approximately RMB5.321 billion.According to NielsenIQ and Syntun data, Kabrita's market share in China's all-channel Goat Milk formula market increased by 2.6 percentage points to 30.2% in 2025. NielsenIQ data further shows that Kabrita has maintained a market share of over 60% in China's imported infant and child goat milk formula market for eight consecutive years (2018–2025). Confirmed by Frost & Sullivan research, Kabrita continues to hold the undisputed position of "No.1 in Global Goat Milk Formula by Both Sales Volume and Sales Value", underscoring its unassailable market leadership.NielsenIQ data also indicates that the Company's cow milk formula business has stabilised its market share, marking the full conclusion of the transitional impact arising from earlier internal integration and channel restructuring. As of the date of this announcement, Ausnutria's Hyproca brand has been awarded dual certifications by iiMedia Research, namely "No.1 in National Sales of Comprehensive Nutrition Infant Formula in 2025" and "Pioneer of Comprehensive Nutrition Infant Formula in China", marking the third consecutive year that Hyproca has topped the comprehensive nutrition formula sales rankings.In 2025, the Company successfully completed the registration of 24 products across 8 series under the New National Standard 2.0 and launched 6 infant formula products across 2 series as well as 25 modulated milk powder products, offering consumers a wider range of functionalised and differentiated product choices. Kabrita was awarded the First Prize for Technological Advancement at the Science and Technology Awards for its research and development project titled "Research and Development of an Infant Formula that Supports Immune Regulation and Alleviates Immune Stress". Meanwhile, Hyproca 1897 was recognized as a "100% Quality Product", with the Company's product strength receiving authoritative endorsement.Lean Management Enhances Quality and Efficiency, Organizational Vitality Continues to FlourishIn 2025, Ausnutria continued to solidify the foundation for long-term development and achieve simultaneous improvements in organizational efficiency and development quality through a series of initiatives, including fully leveraging the momentum of its global supply chain, strengthening internal management effectiveness, establishing the cultural foundation for global collaboration, advancing the construction of its digital intelligence system, and enhancing its sustainable development governance capabilities.Global supply chain momentum unlocks new value growth opportunities. Following Ausnutria's acquisition of Amalthea Group, a Dutch goat cheese company, the Company achieved self-sufficiency in goat whey, a core ingredient for goat milk formula, while also adding cheese to its product portfolio. In 2025, the Company's Goat Cheese business recorded revenue of RMB1.006 billion, further deepening the moat of its internationalization strategy. Concurrently, the Company launched four major goat-based ingredients: goat cheese protein hydrolysate, hydrolyzed goat whey protein powder, goat lactoferrin, and goat colostrum powder. Several of these core goat milk ingredients achieved breakthroughs in commercially viable global applications from scratch, opening up new avenues for value creation for the Company.Internal management effectiveness strengthened to systematically drive sound operations. In 2025, the Company's inventory impairment provisions decreased by 0.9 percentage points year-on-year. Overall asset turnover ratio continued to improve, with inventory turnover days declining by 16 days. The Company continued to advance refined cost management, achieving a notable optimization in its expense ratio, which decreased by 1.4 percentage points year-on-year, with the selling and marketing expense ratio declining by 2.4 percentage points year-on-year.Global systematization of business philosophy to strengthen global strategic synergy. To better align with the pace of business development and reinforce Ausnutria's "one global chessboard" strategic approach, the Company officially released the "Ausnutria Business Philosophy (Overseas Edition)". Co-created through multiple rounds of in-depth discussions among over 60 core managers from Ausnutria's global operations, this business philosophy systematically establishes the core values and management principles for Ausnutria's overseas business. It serves as a tailor-made cultural compass and behavioral benchmark for overseas teams, laying a solid ideological foundation for future business development.Full-chain digital intelligence upgrade, empowering both business and management. The Company has introduced digital intelligence across all stages, from demand research and process design to implementation and execution, enabling traceable decision-making, monitorable processes and quantifiable results. Through the establishment of a data middle platform, intelligent analytical models and other tools, data has become the core enabler for optimising management and supporting business operations, fundamentally safeguarding the sustained and healthy development of the business.Upholding sustainable development principles and actively fulfilling corporate social responsibility. The Company has always adhered to a long-term vision for sustainable development, actively responding to the United Nations Sustainable Development Goals. Centred on three strategic pillars "Better Life, Better Nutrition, Better Environment” the Company has embedded sustainability principles into its operational management framework and across all stages of the value chain. In 2025, Ausnutria organized the "Hyproca Gesang Flower Charity Campaign" for the ninth consecutive year and launched the "Kabrita Care · Worry-free Pregnancy" maternal mental health charity initiative, among other activities. The Company has continued to contribute its corporate strengths in areas such as rural revitalization, education support, national nutrition enhancement and natural disaster relief.In 2025, with the support of consumers, shareholders and all sectors of society worldwide, together with the dedicated efforts of all employees, the Company successfully navigated the multiple challenges arising from economic and industry cyclical adjustments. Looking ahead to 2026, the internal and external environment remains complex and challenging. Ausnutria will continue to put consumers at the center, stay anchored to its operational objectives, accelerate systematic organizational development, drive growth through innovation, enhance efficiency through management excellence, and deliver superior products and performance to reward the trust of all stakeholders, in pursuit of long-term sustainable and high-quality development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
Financial HighlightsFor the year ended 31 December (RMB’000)20252024Change%Revenue1,004,586969,854+3.6%Gross profit544,651539,894+0.9%Profit before tax318,601298,331+6.8%Profit for the year242,548223,618+8.5% HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - 27 March 2026, Shanghai Gench Education Group Limited (“Gench Education” or the “Company”, together with its subsidiaries, the “Group”, Stock Code:1525.HK) -- the leading higher vocational education group in East China and the largest higher vocational education group in Shanghai, delightedly announced its consolidated financial results for the year ended 31 December 2025 (the “Reporting Period”).During the Reporting Period, the Group recorded revenue of approximately RMB1,005 million, representing an increase of 3.6% year-on-year (“YoY”). Gross profit was RMB545 million, up 0.9% YoY; Profit for the year of approximately RMB243 million, a YoY rise of 8.5%. Basic earnings per share attributable to ordinary equity holders of the parent were RMB 0.61, up 7.0% year-on-year. The growth was mainly driven by the increase in student enrolment, optimization of tuition rates and expansion of education-related services. The Group proposes to declare a final dividend of HKD$0.04 per share for 2025. Together with the interim dividend of HK$0.10 per share for the six months ended 30 June 2025, the total dividend for 2025 will be HK$0.14 per share, maintaining a stable dividend policy to reward shareholders.Policy Dividends Deliver with Precision, Lingang Advantages Unleash Development PotentialIn 2025, the national “Outline of the Plan for the Construction of a Stronger Education State (2024-2035)” and the industry-education integration policies of Lingang New Area jointly created a favorable policy environment for the Group’s development. As the only private university in Lingang New Area, Shanghai Jian Qiao University (the “University”) has closely aligned with the regional industrial layout and seized the opportunities brought by the clustering of strategic emerging industries including integrated circuits, life health and high-end equipment manufacturing, achieving precise matching between educational resources and industrial demands. “The Shanghai ‘Lingang Science Innovation Town’ Construction Plan” clearly proposes to leverage the science and technology innovation resources of universities. Taking this opportunity, the University has become a core participant in industry-education integration in Lingang. It has not only obtained special policy and resource support, but also transformed geographical advantages into unique competitiveness through targeted talent training and joint technological research and development. As of 31 August 2025, 77.5% of the University’s 2025 graduates were employed in the Yangtze River Delta region and 59.2% in Shanghai, deeply integrating into the regional development ecosystem.Digital-Intelligent Transformation Yields Remarkable Achievements, Teaching Quality Scales New HeightsDriven by technological innovation in education and teaching upgrading, the University achieved a number of landmark results in curriculum digitalization and smart campus construction in 2025. In terms of curriculum innovation, the University has built a multi-dimensional curriculum system covering “AI + courses”, “industry-education integration courses” and other types. A total of its 26 courses were approved as Shanghai higher education municipal level key courses, among which “AI + courses” accounted for 50%. “Fundamentals of Gemstone Geology and Crystallography” offered by College of Jewelry was successfully selected as a national “Online/Offline Hybrid First-Class Course”, achieving a breakthrough in the construction of national first-class courses. The University has developed a total of 1,253 online open courses, continuously expanding the scale of digital teaching resources. In smart campus construction, the University continues to deepen the upgrading and modification of teaching and scientific research instruments and equipment as well as teaching laboratories, independently developed smart platforms such as the Cloud Teaching Centre and Cloud Examination Centre, and embedded AI, 5G, VR (virtual reality) and other technologies into the teaching reform process. In addition, the University has built the DeepSeek Gench Education Applied Big Model and launched three smart systems for teaching, management and services, achieving refined campus management and personalized services.In terms of faculty development, as of 30 September 2025, among the full-time teachers, the master degree or higher accounted for 86.4%, the doctoral degree accounted for 28.8%, the senior title accounted for 38.6%, and the double-position accounted for 47.8%. The University has promoted the development of teaching staff towards high quality and professionalism through faculty mentoring, specialized training, and encouraging teachers to take part in various teaching competitions. In 2025, the teaching team won numerous awards in national and regional teaching competitions, earning industry-wide recognition for their capabilities. Meanwhile, the University’s disciplinary strength maintained a leading position. According to “2025 First-class Majors Ranking (Application-oriented) in China” by CUAA.net, its 29 majors ranked among top 10 in China, among which 13 majors ranked first nationwide. The employment rate of year 2025 graduates reached 99.4%, the college-entrance rate reached 5.8%, and the rate of studying abroad reached 5.3%, particular with 94 graduates admitted to top 50 universities/colleges and 123 graduates admitted to top 100 universities/colleges in QS World University Rankings. These results demonstrate that the quality of talent training has been widely recognized.Industry-Education Integration Accelerates, Building a Collaborative Ecosystem for School-Enterprise SynergyIn 2025, the University accelerated the construction of an industry-education integrated university and established a “three-in-one” operation model of “Secondary Colleges + Industrial Colleges + Entity Companies”, forming a multi-dimensional collaborative education ecosystem. The University has made comprehensive progress in its industry college development. The University has established the Medical Engineering Industry College and the Live Streaming Economy Industry College, and meanwhile actively drove the construction of the Big Data Industry College, the IC Industry College and the Intelligent Manufacturing Industry College. The “Digital Smart Manufacturing” and “Integrated Circuit” industrial colleges had been awarded as Shanghai municipal key modern industrial colleges. Major platforms were successively launched in a string. The national level platform “IC Packaging and Testing Industry-Talent Collaboration and Innovation Centre” & Lingang Industry-Education Integrated Practice Base was created. Lingang Jewelry Art Centre was opened, integrating public exhibition, entrepreneurship incubation, science generalization & education, appraisal & design, fashion & consumption among other functions. During the year, the University conducted 8 key industry-education integrated projects, and added 20 new industry-education integrated courses with teaching materials, further deepening school-enterprise collaboration. School facilities were continuously improved. The phase four campus facilities were fully operational in March 2025, with a total gross floor area of approximately 86,400 square meters, including a teaching and training building, talent apartments and a multi-functional research and development center, providing a solid foundation for school-enterprise joint research and student practical training.International Cooperation Reaches a New Level, Lifelong Education System Steadily ImprovesThe Group has been deeply engaged in private higher education for 25 years, with its brand reputation and industry position steadily rising. According to CUAA.net, the University has ranked third among Category I private universities in China for five consecutive years and first among private universities in the Yangtze River Delta for seven consecutive years. It has passed the reexamination of “National Model Unit of Civilization” three times and won many honors including the first batch of “Lei Feng Spirit University Demonstration Education Bases” and “Contribution Award for Promoting Lei Feng Spirit in the New Era”. Its quality of education has received wide recognition from society. International business continued to expand. In 2025, the University contracted with 11 overseas famous universities/colleges in Germany, United Kingdom, New Zealand, Thailand and other countries, received cumulatively 43 batches of delegations of overseas famous institutions, and published more than 30 foreign/overseas exchange projects (like UN international NGO training, overseas famous university/college visit, overseas famous enterprise internship), continuously broadening channels for teachers and students to exchange overseas.The lifelong education system has been continuously improved to meet the diverse learning demands of all communities. As of 31 December 2025, the number of adult students of the continuing education programs reached 3,760, and more than 400 types of vocational skill certificate training were provided. In addition, as a continuing education base for high end equipment industry workers and a continuing education base for fashion consumption and logistics industry workers, the University applies for Shanghai “dual system” workers continuing education higher education pilot base (incubation) project, and the project is initiated.Looking to the future, Mr. Zhao Donghui, Chairman of the Board and Executive Director of Gench Education, stated: “The steady growth of the Group’s performance in 2025 confirms the effectiveness of the high-quality development strategy. Going forward, we will continue to take digital and intelligent transformation as the driver, deepen the industry-education integration collaborative education model, seize the historic opportunity of building Lingang New Area into a world-class science innovation town, further optimise the professional layout, enhance the teaching capacity and improve the campus ecosystem. We are committed to preliminarily completing the transformation of an industry-education integrated university by 2030 and fully accomplishing it by 2035, building a world-class private university with international influence, and sharing the dividends of high-quality development of vocational education with all shareholders.”About Shanghai Gench Education Group LimitedGench Education (Stock Code: 1525.HK) is a higher vocational education group which provides undergraduate education and junior college education, focusing on high-quality schooling for the provision of excellent education for students. The Group operates Shanghai Jian Qiao University, being the domestic leading private university, at Lingang New Area of China (Shanghai) Pilot Free Trade Zone. As measured by the number of full-time students enrolled in the 2025/26 school year, the University is the largest private university in Shanghai and is also a leading private university in the entire Yangtze River Delta. According to CUAA.net, the University ranked third among all category I private universities in China for five consecutive years and first among private universities in the Yangtze River Delta for seven consecutive years. Over 25 years of operation, the schooling quality of the University ranked in the forefront of peer universities, which has accumulated a solid brand reputation. Since 2004, the University has been consecutively awarded “Shanghai Civilized Unit” over 18 years. The University has won numerous honorary titles such as “National Model Unit of Civilization”, “Shanghai Garden Unit”, “Shanghai Safe and Civilized Campus”, etc. The University has also been granted reputable title of “Lei Feng Spirit College Demonstration Education Base” among the first batch of universities in the PRC in April 2024, and was awarded the “Contribution Award for Promoting Lei Feng Spirit in the New Era” in September 2024.This press release is issued by Porda Havas International Finance Communications Group on behalf of Shanghai Gench Education Group Limited. For further information, please contact:Porda Havas International Finance Communications GroupE-mail: gench.hk@pordahavas.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SYDNEY, AU, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - Vantage Goldfields Limited (Vantage Goldfields) owns Vantage Goldfields Pty Ltd (VGL), Barbrook Mines Pty Ltd (Barbrook) and Makonjwaan Imperial Mining Company (Pty) Ltd (MIMCO) (collectively the Vantage Companies), which own the Lily and Barbrook mines in South Africa. The Vantage Companies are currently in business rescue in South Africa, which is the legal process that assists financially distressed companies restructure, or otherwise avoid liquidation.An announcement was made on 26 March 2026 by TSX-V listed Lions Bay Capital Inc. (Lions Bay), which the Vantage Companies believe is misleading to investors and fails to disclose material information (the Announcement). That Announcement referred to Lions Bay receiving approval from a business rescue practitioner (BRP) of the Vantage Companies and calling a meeting of creditors to approve business rescue plans for the Vantage Companies.The Announcement is misleading and fails to disclose relevant material information regarding the Vantage Companies and Lions Bay proposal, including:While the Announcement referred to a Business Rescue Practitioner (BRP) (being Mr Devereux) approving the Lions Bay proposal, it failed to disclose that the Vantage Companies have two appointed BRPs and the second BRP has not approved the Lions Bay's proposal. Both BRPs have to approve a proposal in order for it to be presented to creditors. The second BRP was appointed by the Boards of the Vantage Companies, and his appointment was confirmed by the Companies and Intellectual Property Commission (CIPC), the corporate regulator in South Africa.The second BRP was appointed to ensure that all viable proposals for the rescue of the Vantage Companies are properly considered and that a business rescue is then properly and lawfully implemented for the benefit of all stakeholders, including creditors, former employees and the local community, as soon as possible.Vantage Goldfields as the owner of the Vantage Companies and Lily and Barbrook mines, has received a number of viable proposals for the rescue of the Vantage Companies and the reopening of those mines, which should be properly considered by the BRPs. These proposals should result in a better outcome for creditors and other stakeholders of the Vantage Companies than the Lions Bay proposal.Mr. Devereux acted unilaterally and unlawfully in purporting to approve an offer from Lions Bay and convene a meeting of creditors of the Vantage Companies. Vantage Goldfields believes that Mr. Devereux misled such creditors by failing to disclose that Lions Bay does not have the necessary US$40 million in funds to be able to complete its proposal.The Announcement failed to disclose that for the Lions Bay proposal to be able to be implemented, an approval from a BRP is not legally sufficient to be able to implement that proposal, and that proposal would need to be approved by specified majorities of creditors of each of the Vantage Companies. Vantage Goldfields has been informed by the largest secured creditor of the Vantage Companies that it does not support and will not vote in favour of the Lions Bay proposal at the necessary meetings of creditors, on its current terms and given that Lions Bay does not have all the necessary funds to complete the proposal. That creditor also has not agreed to release its securities over the asset of the Vantage Companies.Therefore, the necessary approvals of creditors will not be obtained, and the Lions Bay proposal will not be able to be implemented as currently proposed.Vantage Goldfields intends to ensure that all viable proposals are properly considered for the business rescue of the Vantage Companies, and that the business rescue process is progressed and implemented properly in accordance with South African law. Vantage Goldfields remains fully committed to reopening the Lily and Barbrook mines for the benefit of all creditors, former employees, affected persons and other stakeholders of the Vantage Companies.Stephen TurnerChairman-Vantage Goldfieldsst@stephenturner.com.auThis press release contains forward-looking statements, including statements about our future operations, plans, objectives, expectations, estimates, forecasts, or projections. Forward-looking statements are inherently subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or outcomes to differ materially from those expressed or implied.Under Australian law, statements about future matters must be based on reasonable grounds at the time they are made or they may be considered misleading. We believe the forward-looking statements in this release are based on reasonable grounds; however, events or circumstances may cause actual results to differ.These risks and uncertainties may include, among other things, changes in market conditions, economic factors, industry developments, operational challenges, regulatory changes, and other factors known or unknown to the company.Forward-looking statements speak only as of the date of this release, and except as required by law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or changed circumstances.Source: Vantage Goldfields Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - In the Hong Kong stock market, the key to consistently winning investor trust lies not just in periodic earnings growth, but in the ability to stably transform operating results into shareholder returns. According to the latest 2025 annual results report disclosed by Shoucheng Holdings (0697.HK), the company proposes a dividend of 780 million HKD, corresponding to an average annual market value dividend yield of approximately 5.6%. Looking at the long term, since its strategic transformation in 2018, the company has continuously advanced business transformation and structural optimization, leading to steady improvements in profitability and cash flow quality. It has maintained stable dividends for many consecutive years, with a cumulative dividend scale of approximately 6 billion HKD over eight years, shifting the investment logic from "growth expectations" toward "balancing both growth and returns".It is noteworthy that this dividend does not rely on high leverage or short-term overdrafts; rather, it is a proactive return built on improved balance sheets, enhanced operating quality, and optimized cash flow. As of December 31, 2025, the company's bank balances and cash stood at 3.671 billion HKD, with total borrowings of 979 million HKD. The cash-to-interest-bearing debt coverage ratio is approximately 3.75 times, demonstrating strong dividend sustainability and a significant financial safety margin.Over the past eight years, Shoucheng Holdings has gradually formed a smart infrastructure asset service system centered on parking asset management, industrial space management, REITs investment, and equity investment, constructing a composite model of "operational efficiency + asset management + capital circulation". Mature businesses such as parking and industrial parks continue to provide steady cash flow, serving as the practical foundation for the company's dividends. Meanwhile, REITs investments, the robotics ecosystem, and emerging industry funds further open up space for profit realization and valuation enhancement.Among these, the robotics business is becoming a significant incremental driver of Shoucheng Holdings' long-term value. In recent years, the company has continuously refined its robotics layout around "investment + operations + ecosystem," systematically investing in several leading robotics enterprises. Through scenario integration, channel construction, and industrial services, it has pushed projects from technical verification to commercial implementation. As relevant companies accelerate financing, see valuation increases, or move toward IPOs, the robotics segment is expected to continuously strengthen the company's mid-to-long-term profit release and shareholder return capabilities.Furthermore, in the latest Chairman's Statement, Chairman Zhao Tianyang explicitly expressed "gratitude" to investors and continued to emphasize "creating long-term value for investors". This statement is not merely a declaration of attitude but sends a clear signal: Shoucheng Holdings is placing shareholder returns and long-termism in a more prominent position. For the market, the significance of eight years of continuous dividends has long transcended a simple profit distribution; it serves as a more certain anchor of confidence for long-term capital amidst complex economic cycles. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, March 23, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in Greater China, including Chinese Mainland, Hong Kong, Macao and Taiwan region.Under the terms of the agreement, Everest will pay CORXEL an upfront payment of US$30 million (equivalent to approximately RMB344,895,000), as well as potential development milestone payments of up to US$20 million (equivalent to approximately RMB137,958,000). As part of this agreement, Everest will be assigned and transferred rights, interests, claims, duties, obligations and liabilities (other than certain excluded liabilities) under the Milestone License Agreement entered into by CORXEL in May 2021 and certain related ancillary agreements.CARDAMYST™ (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker as administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As a rapid-acting treatment option, CARDAMYST can be self-administered outside the emergency department or other healthcare settings, enabling patients to actively manage episodes and gain greater control over their condition. In addition to its approved indication for PSVT, etripamil nasal spray is also under clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials have shown encouraging results, and Phase III trials are planned, with the potential to further extend its therapeutic impact to a broader patient population.In China, the New Drug Application (NDA) for etripamil nasal spray was accepted by the National Medical Products Administration (NMPA) on January 17, 2025 and is expected to receive approval in the third quarter of 2026.PSVT is characterized by abnormalities in the heart's electrical system that cause sudden unexpected and often severely symptomatic episodes of rapid heart rate. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.AFib-RVR is a type of irregular heart rhythm, characterized by an irregular and elevated heart rate. Its onset is typically gradual, episodes are less likely to terminate spontaneously, and the condition tends to recur, significantly increasing the risk of thromboembolism and serious complications such as stroke and heart failure. In China, atrial fibrillation affects an estimated 1.6% of the population, representing nearly 20 million patients, and is expected to increase with an aging population. Both PSVT and AFib-RVR are associated with a loss of control and a significant psychological burden for patients.Overall, the combined patient population for PSVT and AFib-RVR exceeds 25 million, representing a significantly unmet clinical need that urgently requires more convenient and more effective treatment options.In terms of clinical data, the NDA for etripamil nasal spray was accepted by the NMPA based on data from the pivotal global Phase 3 RAPID study and the China Phase 3 JX02002 study. Both trials met their primary endpoints. Overall, the treatment emergent adverse events (TEAEs) were comparable between the etripamil and placebo groups. The FDA approval of CARDAMYST was supported by a robust clinical program that included safety data from more than 1,800 participants across more than 2,000 PSVT episodes. This included the Phase 3 RAPID trial, a global, randomized, double-blind comparison of etripamil versus placebo, published in The Lancet in 2023. The RAPID trial achieved its primary endpoint, with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared with 31% on placebo (N=85) (HR = 2.62; p<0.001). The median time to conversion was 17 minutes (95% CI: 13.4, 26.5) for etripamil versus 54 minutes (95% CI: 38.7, 87.3) for placebo. Etripamil nasal spray is also under clinical development for AFib-RVR. In the randomized, controlled Phase-2 ReVeRA study, etripamil demonstrated rapid and significant reduction in ventricular rate in patients with AFib-RVR, achieving its primary endpoint. A greater number of patients receiving etripamil achieved a ventricular rate of less than 100 bpm (58.3%) than those receiving placebo (4%). The safety profile was consistent with previous studies.From a strategic perspective, this transaction is also seen as an important step for the Company in implementing 2030 Strategy. Driven by its 2030 Strategy, and led by Mr. Yifang Wu, Chairman of the Board, Everest is accelerating growth through a dual-engine approach that combines strategic business development partnerships with in-house R&D. This transaction further strengthens Everest's expanding cardiovascular franchise, building on recent strategic initiatives and reinforcing the Company's disciplined approach to constructing focused therapeutic verticals with meaningful lifecycle expansion potential. Through continued advancement of its pipeline and product portfolio globally, Everest aims to deliver innovative therapies to more patients, create sustainable long-term value, and advance its position to become a leading global biopharmaceutical company."We are pleased to collaborate with CORXEL, this agreement marks an important step in our continued expansion in the cardiovascular field and a meaningful milestone in advancing our growth 2030 strategy," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "CARDAMYST is currently the only therapy designed for at-home self-administration to enable the acute termination of PSVT and AFib-RVR episodes, addressing a significant unmet medical need among patients in China. We will leverage our clinical development expertise and established commercialization platform to accelerate its advancement and future launch in Greater China, while further strengthening our cardiovascular franchise and unlocking its broader potential across atrial arrhythmias."As the registration and commercialization of Etripamil nasal spray progress, the company aims to further expand its cardiovascular portfolio. Leveraging its established clinical development and commercialization capabilities, Everest Medicines will accelerate the delivery of innovative assets, advance its 2030 strategy, and bring more treatment options to patients. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has become critical for enterprises to forge core strategic competitiveness in the era of AI.As a leading provider of AI real-time data infrastructure and analysis services in China, Xunce Technology is rapidly solidifying its core position in AI data, driven by industry tailwinds, full-chain technological capabilities and diversified growth engines. Amid the unfolding landscape of the intelligent economy, this ten-year industry stalwart is entering a pivotal window for structural revaluation.Token Value Restructuring: Making Every Data Access Quantifiable and MonetizableFounded in 2016, Xunce Technology has built a full-chain technological system spanning data acquisition, cleansing, standardization, real-time computing and large- model optimization over a decade of development. With AI Data Agent at its core, the Company specializes in millisecond-level real-time data processing, serving a diversified portfolio of industries including finance, urban governance, high-end manufacturing, healthcare, robotics, satellite applications, low-altitude economy, electric power, power grids and energy.As the era of AI inference unfolds, Token is evolving from mere “fuel” to a form of “hard currency”. Maximizing the value of each individual Token has emerged as a central challenge in the large-model inference era. Today, general-purpose large models typically rely on a “computing power for precision” approach, where every inference run generates substantial wasteful Token consumption. Should inference fail, all Tokens expended in the process are lost entirely, which is a common pain-point plaguing general AI systems.By contrast, vertical AI solutions equip general large language models with an external industry “brain” powered by domain-specific data. At its core, such solutions optimize inference logic via business-aware models, enabling upfront task feasibility validation and eliminating Token waste at the source. With deep expertise in professional vertical domain data modeling, Xunce Technology leverages its extensive portfolio of high-quality, scenario-specific proprietary data to act as an “efficiency multiplier” for every Token invocation. This structure translates Token consumption into higher-precision outputs while securing maximal result certainty. Crucially, the Company is developing full-chain capabilities spanning data metering, pricing and settlement, enabling quantifiable and monetizable measurement for every data access. By elevating per-unit Token efficiency, it delivers enhanced business value to enterprise clients.Aligned with this strategy, Xunce’s platform features a “LEGO-inspired” modular architecture, enabling clients to flexibly compose modules tailored to their specific needs. This “assemble-on-demand, adapt-in-real-time” design fosters deep and long-term customer stickiness. The Company also employs a highly flexible pricing framework, with fees structured around module count, processing throughput and other key metrics. Supported by subscription, transaction-based and Token-based payment models, its pricing mechanism precisely aligns with diverse client demands.Currently, Xunce Technology is fully building a full-chain data measurement and settlement system. It is exploring pricing mechanisms tied to large model inference frequency and module usage count, allowing customers to pay for effective Tokens rather than raw computing power consumption.Inflection Point Reached, Profitability ConfirmedDriven by Token value restructuring and innovative business models, Xunce Technology has delivered robust performance and reached a historic inflection point. In H2 2025, the Company posted an adjusted net profit of RMB 50 million, achieving its first positive profitability. Meanwhile, revenue rose from RMB 197.85 million in H1 2025 to RMB 1,086.81 million in H2, representing a 449.32% quarter-on-quarter surge. Amid rapid business expansion, the Company has witnessed a substantial improvement in profitability.Explosive Revenue GrowthReturn to Profit in H2Doubled ARPU & Per Capita GrowthImproved Cash Flow & Operating Metrics+103% Y/YNarrowed by 33%+105% Y/YSignificant Improvement2025 full-year revenue YoY growth2025 full-year adjusted net loss2025 ARPU YoY growth2025 net operating cash flow+449% H/HRMB 50 million+135% Y/YAmple cash on hand in 20252025 H2 revenue HoH growth2025 H2 adjusted net profit2025 per capita revenue YoY growthAverage collection period decreased in 2025For the full year, the Company posted total operating revenue of RMB 1,284.66 million, representing a substantial year-on-year increase of 103.28% and successfully breaking the key milestone of RMB 1 billion in revenue. This signifies that the Company has evolved from an early-stage, technology-driven startup into a new era of platform-based development with scalable and replicable business models.Furthermore, the Company’s combined gross proceeds for 2025 amounted to approximately RMB 792.08 million, representing a substantial increase of 63.44% compared to approximately RMB 484.63 million in the previous year. In terms of adjusted net loss, after deducting one-off non-recurring gains and losses, the Company’s adjusted net loss for 2025 was RMB 54.84 million, representing a significant narrowing of 33% from RMB 82.37 million in 2024.Notably, the Company achieved combined gross margin of 62% in 2025, exceeding that of Cambricon (55%), a leading AI chip provider, and far outpacing general large- model developer Minimax (25.4%). This underscores its high-value strategic positioning and resilient business model in the AI data infrastructure sector.In terms of R&D investment, Xunce Technology has also maintained efficient growth conversion. In 2025, the Company’s R&D expenditure reached RMB 450.44 million, with R&D expenses accounting for 48% of revenue, driving a 105% year-on-year increase in operating revenue. For comparison, Minimax’s R&D expenditure accounted for as high as 219% of its revenue, with a revenue growth rate of 159%. Xunce achieved a comparable expansion pace with a lower R&D intensity.As revenue scale continues to expand and gross margin in new industries gradually stabilize, the Company’s short-term objective is to achieve an inflection point in adjusted net profit. Looking ahead, as the industries already deployed enter a period of margin stabilization and Token-based payment and revenue-sharing models gain accelerated traction, its net profit is poised to improve at an accelerated rate.Driven by Diversified Growth Engines, Business Structure Continuously OptimizedThe robust revenue growth is not accidental, but underpinned by Xunce Technology’s multi-dimensional, systematically structured growth framework.Accelerate cross-industry replication. The Company currently covers 9 major industries, benchmarking Palantir’s 17 industries and leaving ample room for horizontal expansion. Xunce Technology is rapidly deepening its presence in key national strategic sectors such as asset management, telecommunications, electric power, urban management, high-end manufacturing, healthcare, energy, robotics training platforms and commercial aerospace. For each new industry, the Company first completes industry-specific data accumulation over 3 to 5 years, enabling rapid replication and scaled deployment across peer customers thereafter.The business model fosters deep customer value enhancement. As customers evolve from single-module adoption to multi-module deployment, and from pilot trials to full integration into core business workflows, substantial upside potential in ARPU remains. By synergistically lifting Token invocation volume, module usage count and per-Token value, the Company will unlock a new dimension of growth.Steadily expand overseas business and establish a global layout. The Company targets raising its overseas revenue share to 10% to 15% in 2026, and will further escalate its globalization strategy during 2027 and 2028, unlocking new avenues for sustained long-term growth.Cultivate a strategic cooperative ecosystem to forge deep integration with upstream and downstream partners in computing power and algorithms. Xunce Technology is engaging in in-depth collaboration with leading domestic GPU providers and large language model enterprises to build a one-stop solution encompassing “infrastructure computing power, upper-layer applications and data governance,” further solidifying its core position in the AI data infrastructure sector. Pioneer cutting-edge applications to seize commanding heights in future industries. From robotics data platforms to commercial aerospace, low-altitude economy and power grid systems, Xunce Technology has taken the lead in extending AI infrastructure to emerging sectors with stringent demands for real-time performance and operational reliability. Such mission-critical scenarios with ultra-high requirements for data timeliness and stability serve as a rigorous validation of the Company’s technological advantages. The Company will continue to ramp up R&D investment in frontier fields, refine its technical capabilities through high-end application scenarios and unlock new high-growth, high-value growth tracks for long-term development.Evolving from Data Services to Core AI Economy Infrastructure: Building Sustainable Competitive BarriersFrom a macro perspective, the artificial intelligence data sector is witnessing a profound convergence of five defining trends: a surge in demand for real-time, secure, high-quality data in the era of AI Agent; the rise of domain-specific models elevating professional data as a critical enabler for industry-wide intelligent upgrading; standardization of data interfaces driven by next-generation AI operating systems including Open Claw, positioning Xunce Technology as a core data Token provider; Token-based payment emerging as a new paradigm for the data element market; and the implementation of data asset capitalization policies, spurring a sharp rise in enterprises’ mandatory investment in data governance.At the intersection of these five pivotal trends, Xunce Technology has established a robust fundamental logic for sustained long-term growth. The Company has evolved beyond a traditional data infrastructure provider to become a critical “connector” and “enabler” linking large models, computing power and cloud vendors. By integrating upstream models, downstream computing power and horizontal collaboration with cloud vendors, the Company delivers irreplaceable data-centric value to its enterprise clients.The Company stresses that it shares a natural upstream-downstream synergy with general large-model providers, rather than a competitive dynamic. Analogous to the deep collaboration between GPU manufacturers and model developers, the value of Xunce Technology lies in a mutually reinforcing cycle: the wider the adoption of models by its clients, the greater the opportunity for the Company to deliver services and generate incremental value for clients.Notably, in contrast to niche market players offering only isolated modules such as data cleansing or computing engines, Xunce Technology’s core differentiation lies in its full-process coverage and outcome-driven accountability. The Company provides an end-to-end solution spanning data acquisition, cleansing, standardization, modeling, real-time computing and model tuning, ensuring that final data delivered to clients is clean, accurate, real-time and accessible for model invocation at millisecond latency. Furthermore, through deep integration into clients’ private clouds or on-premises environments, the Company acts as a dedicated data steward, fostering exceptional customer stickiness and forging robust, sustainable competitive barriers.Currently, the Company’s product portfolio and solutions feature more than 300 functional modules, covering a full spectrum of scenarios from data infrastructure to upper-layer analytics applications. In 2025, its active paid clients base reached 230, with an outstanding customer retention rate of 90%. ARPU increased substantially from RMB 2.72 million in 2024 to RMB 5.59 million in 2025, representing a year-on-year growth of over 103%.As algorithms become increasingly open-source and computing power tends toward standardization, what truly sets companies apart lies in data — particularly industry data that has undergone sophisticated governance and can effectively empower large models. Backed by a decade of deep industry expertise, Xunce Technology has established a substantial and sustainable competitive barrier in this domain.ConclusionFrom an early-stage private equity tool provider to a cross-industry AI data infrastructure builder, and from a module supplier to a Token-priced core platform, Xunce Technology has remained committed to unlocking data as a scarce, strategic resource that is freely circulable, readily callable and empowered to drive high-quality decision-making.Amid the rapid emergence of new intelligent economic paradigms, the Company stands at the threshold of a fundamental structural revaluation, with the potential to enter the RMB 100-billion market cap camp. It is a competitor to none, but an indispensable partner to all. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 随着人工智能加速迈向推理阶段，企业级AI迎来规模化落地，Token消耗呈指数级攀升，数据需求进入全新发展阶段。在这一趋势下，高质量、结构化、场景化的专业数据，正成为AI时代企业构建核心战略竞争能力的关键所在。作为中国领先的AI实时数据基础设施及分析服务商，迅策科技得益于赛道红利，凭借全链路技术能力与多元增长引擎驱动，正加速确立其在AI数据层的核心地位。随着智能经济新形态的全面展开，这家深耕十年的企业正迎来结构性价值重估的窗口期。Token价值重构：让每一次数据调用都可量化、可计价迅策科技成立于2016年，历经十年发展，已构建起覆盖数据获取、清洗、标准化、实时计算至大模型调优的全链路技术体系。公司以AI Data Agent为核心，专注于毫秒级实时数据处理，服务领域涵盖金融、城市运营、高端制造、医疗、机器人、卫星、低空经济、电力、电网及能源等多元化产业。在AI推理时代开启的当下，Token正从"燃料"进化为"硬通货"。如何将每一个Token的价值最大化，成为大模型推理阶段的核心命题。当前，通用大模型普遍采用"用算力换精度"的策略，每一次推理都伴随着大量无效Token消耗。一旦推理失败，前期投入的Token全部作废——这是通用AI面临的共同困境。相比之下，垂类AI解决方案则是用行业数据为通用大模型安装一个"外脑"。其核心在于用业务模型优化推理路径，提前判断任务可行性，从源头避免Token浪费。长期深耕专业垂类数据建模领域的迅策科技，凭借其多年积累的高质量、场景化垂类数据，相当于为每一次Token调用加装了"增效器"，在消耗 Token 时换取更高精度的结果，实现最高的产出确定性。更为关键的是，公司正在构建全链路的数据计量、计费、结算能力，使每一次数据调用，都可量化、可计价，通过提升每单位Token的有效性，为客户带来更高的业务价值。围绕这一思路，迅策科技的平台采用"乐高式"模块化架构，让客户可以根据自身需求灵活组合模块，实现"按需装配、随需而变"，建立深度黏性。公司在定价与收费模式上亦遵循灵活设定，基于模块数量、处理速度等维度，销售采用订阅制、交易制以及按Token收费制的模式，以精准匹配客户需求。目前，迅策科技正全力构建全链路的数据计量与结算体系，探索按大模型调用次数与模块应用个数等维度计价，让客户为"有效Token"付费，而不是为算力消耗买单。业绩拐点已现，盈利能力得到验证在Token价值重构背景与商业模式创新的推动下，迅策科技业绩表现强劲，迎来历史性拐点：2025年下半年，公司实现经调整净利润0.5亿元，首次实现半年度正向盈利。此外，公司在2025年上半年实现营收1.98百万元，下半年营收跃升至10.87百万元，环比激增449%。公司在高速扩张的同时，盈利能力已开始实质性释放。全年来看，公司实现营业收入达1,284.66亿元，较上年同期大幅增长103.28%，成功跨越"十亿营收"这一关键门槛，标志着公司已从早期技术驱动的初创阶段，正式迈入可规模化复制的平台化发展新纪元。此外，2025年公司综合毛利约为人民币792.08百万元，较上年度约人民币484.63百万元大幅增加63.44%。经调整净亏损方面，扣除一次性非经常性损益后，公司2025年度经调整净亏损为人民币54.84百万元，较2024年度的82.37百万元大幅收窄33%。值得注意的是，2025年公司综合毛利率达62%，不仅高于以AI芯片为核心业务的寒武纪（55%），更远超通用大模型公司Minimax（25.4%），体现出其在AI数据基础设施领域独特的高价值卡位与商业模式韧性。在研发投入方面，迅策科技亦保持了高效的增长转化。2025年公司研发开支达450.44百万元，研发支出占收入比重为48%，驱动营业收入实现105%的同比增长；相比之下，Minimax研发支出占比高达219%，收入增幅为159%。迅策以更低的研发强度，实现了接近同等级别的扩张速度。随着收入规模持续扩大、新行业毛利逐步收敛，公司短期盈利目标为实现经调整净利润迎来拐点。未来随着已投入行业陆续进入毛利收敛期，以及Token付费与分成模式加速落地，公司净利率有望加速提升。多元增长引擎驱动，业务结构持续优化业绩的强劲增长并非偶然，背后是迅策科技多维驱动、系统推进的增长逻辑。加速跨行业复制。公司目前覆盖9大行业，对标Palantir的17个行业，横向拓展空间广阔。迅策科技正加速向资管、电信、电力、城市管理、高端制造、医疗、能源、机器人训练平台、商业航天等国家重点发展的行业纵深拓展。每进入一个新行业，公司先用3-5年完成行业数据沉淀，随后便可实现同行业客户的快速复制推广。商业模式驱动客户价值深耕。 随着客户从单一模块走向多模块部署、从局部试用走向核心业务流程嵌入，ARPU值仍有显著提升空间。通过Token调用次数、模块应用数量及单次Token价值的协同提升，公司将打开全新的增长空间。稳步开拓海外业务，构建全球化布局。公司规划2026年海外收入占比提升至10-15%，2027-2028年持续提升全球化战略，为长期增长开辟新的空间。构建战略合作生态，与算力及算法上下游深度绑定。迅策科技正与国内头部GPU厂商及大模型公司深度合作，构建"底层算力+上层应用+数据治理"的一站式解决方案，进一步巩固其在AI数据层的核心地位。开拓前沿应用，抢占未来产业制高点。从机器人数据平台到商业航天、低空经济、电力电网，迅策科技率先将AI基础设施延伸至对实时性、可靠性要求极高的新兴领域，这些对数据实时性、可靠性要求极致的场景，正是公司技术优势的最佳试金石。公司将持续加大在前沿领域的研发投入，以尖端场景锤炼技术能力，为未来发展开辟高增长、高价值的新赛道。从数据服务商到AI经济核心基础设施，构建深厚竞争壁垒宏观层面来看，人工智能数据领域正迎来五大趋势的深度交汇：AI Agent时代对实时、安全、高质量数据的需求爆发；垂类模型崛起使专业数据成为行业智能化升级的关键要素；Open Claw等新一代AI操作系统将数据接口标准化，迅策科技正成为核心数据Token供应商；Token化付费成为数据要素市场的新范式；数据资产入表政策落地，企业对数据治理的刚性投入需求激增。在这五大趋势的交汇点上，迅策科技逐步构筑起长期发展的坚实底层逻辑。迅策科技不再只是数据基础设施提供商，而是连接模型、算力、云厂商的"连接器"与"赋能者"。向上连接模型，向下连接算力，横向协同云厂商，最终为客户提供不可替代的数据价值。公司强调，其与通用大模型公司是天然的上下游合作关系，而非竞争关系。正如GPU厂商与模型公司深度合作一样，迅策科技的价值在于：客户使用的模型越多，公司的服务机会越多，为客户创造的价值也越多。值得关注的是，与市场上仅做数据清洗、或仅做计算引擎的单一模块厂商不同，迅策科技的核心差异在于全流程覆盖与为结果负责的能力。从数据获取、清洗、标准化、建模、实时计算，到模型调优，提供端到端解决方案，确保最终输出给客户的数据是干净的、准确的、实时的、可被模型秒级调用的。同时，公司深度嵌入客户的私有云或本地系统，扮演"数据管家"角色，形成极高的客户粘性与竞争壁垒。目前，公司产品与解决方案拥有超过300多个功能模块，覆盖从数据基础设施到上层分析的全场景。2025年，公司的付费客户活跃量达到230家，客户留存率高达90%。ARPU值从2024年的272万元，再大幅提升2025年559万元，同比增幅超过103%。当算法走向开源，算力趋于标准化，真正拉开差距的，是数据——尤其是经过深度治理、能够驱动大模型的行业数据。迅策科技凭借十年深耕，已在这一领域构建起深厚的护城河。结语从早期私募工具到跨行业的AI数据基建，从"模块供应商"到"Token计价平台"，迅策科技始终致力于让数据成为真正可流动、被调用、可驱动决策的稀缺资源。在智能经济新形态加速到来的今天，这家公司正站在结构性重估的起点上, 或进入千亿市值阵营。它不是任何人的竞争者，而是所有人都需要的合作伙伴。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%, increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
